Geron Corporation GERN
0.87 USD -0.04 (-4.63%)
Regular-session close
0.89 +0.02 +2.45%
After hours · Nov 20, 6:53 PM ET
0.8615 Day range 0.925
0.8707 52-week range 1.95
- YTD
- -34.04%
- 1 year
- -20.85%
News
globenewswire.com Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people…benzinga.com Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six…
benzinga.com Geron Q3 2026 Earnings Call Transcript Geron (NASDAQ:GERN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…benzinga.com Wedbush Maintains Outperform on Geron, Lowers Price Target to $5 Wedbush analyst Robert Driscoll maintains Geron (NASDAQ:GERN) with a Outperform and lowers the price target from $6 to $5.
benzinga.com Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth Geron stock plunges as the company halts its Phase 3 IMpactMF trial, refocusing its resources on commercial hematology and global expansion.
benzinga.com Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings U.S. stocks were mixed; Dow and S&P 500 rose while Nasdaq slipped. Brinker beat estimates and raised guidance; oil jumped 3.4%.
